PRTG - PORTAGE BIOTECH INC.

5.33
-0.200   -3.752%

Share volume: 87,336
Last Updated: 04-07-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.00%

PREVIOUS CLOSE
CHG
CHG%
$5.53
-0.20
-0.04%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
8%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 20%
Performance
5 Days
-11.61%
1 Month
33.25%
3 Months
13.16%
6 Months
-27.68%
1 Year
894.30%
2 Year
70.83%
Key data
Stock price
$5.33
P/E Ratio 
0.00
DAY RANGE
$5.15 - $5.94
EPS 
N/A
52 WEEK RANGE
$0.10 - $23.01
52 WEEK CHANGE
$985.54
MARKET CAP 
3.618 M
YIELD 
N/A
SHARES OUTSTANDING 
1.049 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-15-2025
BETA 
1.56
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$210,301
AVERAGE 30 VOLUME 
$1,602,482
Company detail
CEO: Ian B. Walters
Region: US
Website: portagebiotech.com
Employees: 6
IPO year: 2007
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Portage Biotech Inc. researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology.

Recent news
loading